Article
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.
Seminars in immunology - 1 Oct 2008
Sampson John H, Archer Gary E, Mitchell Duane A, Heimberger Amy B, Bigner Darell D
Abstract excerpt
Conventional therapies for malignant gliomas (MGs) fail to target tumor cells exclusively, such that their efficacy is ultimately limited by non-specific toxicity. Immunologic targeting of tumor-specific gene mutations, however, may allow more precise eradication of neoplastic cells. The epidermal growth factor receptor variant III (EGFRvIII) is a consistent tumor-specific mutation that is widely expressed in MGs...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.